
Artivion (AORT) Stock Forecast & Price Target
Artivion (AORT) Analyst Ratings
Bulls say
Artivion Inc has demonstrated a notable increase in operating margin, reaching 17.8%, which reflects a significant year-over-year improvement of 770 basis points, surpassing previous estimates. The company anticipates ongoing growth prospects with expected enhancements in gross margin and EBITDA margins for 2025, supported by an increase in research and development investments. Strong sales growth across its key product lines, including aortic stent grafts and On-X products, along with the potential revenue boost from the upcoming AMDS product launch, further underpins a positive outlook for Artivion's financial performance.
Bears say
Artivion Inc is facing several significant challenges that contribute to a negative outlook on its stock. The company's fourth-quarter revenue growth declined to 3.5%, a decrease from 9.5% in the previous quarter, primarily due to a cybersecurity incident that resulted in a revenue headwind of approximately $4.5 million, exceeding the quarterly revenue miss of $3.5 million. Furthermore, the bear case scenario suggests that revenue growth may slow to mid- to high-single digits, driven by disappointing product launches and underwhelming international expansion, alongside a reduction in gross margin of 200 basis points year-over-year.
This aggregate rating is based on analysts' research of Artivion and is not a guaranteed prediction by Public.com or investment advice.
Artivion (AORT) Analyst Forecast & Price Prediction
Start investing in Artivion (AORT)
Order type
Buy in
Order amount
Est. shares
0 shares